- Previous Close
0.3025 - Open
0.2995 - Bid 0.3050 x --
- Ask 0.3200 x --
- Day's Range
0.2995 - 0.3000 - 52 Week Range
0.2970 - 2.3750 - Volume
0 - Avg. Volume
186 - Market Cap (intraday)
3.025M - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2900 - Earnings Date Nov 14, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
www.enveric.comRecent News: SLZA.F
View MorePerformance Overview: SLZA.F
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLZA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLZA.F
View MoreValuation Measures
Market Cap
3.07M
Enterprise Value
-3.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.50%
Return on Equity (ttm)
-206.10%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.59M
Diluted EPS (ttm)
-2.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.04M